Description: Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2].